Celgene (NASDAQ:CELG) has compiled preliminary 2012 results, and provided guidance for future periods that anticipates a doubling of sales by 2017, the company detailed in a press release. For fiscal 2012, the biotech firm believes it will post adjusted, diluted earnings per share of around $4.90, which is at the upper end of its previously-announced guidance range. Net product sales should come in at around $5.4 billion.
For future periods, the company anticipates it will post net product sales of $6 billion in 2013, an 11% increase on a year-over-year basis. Meanwhile, it is expecting EPS of $5.50-$5.60.
For 2017, Celgene has targeted a sales figure of $12 billion, double the expected level of 2013. It is also targeting EPS of $13-$14 that year.
The company will discuss its official 4Q and fiscal 2012 results in a conference call on January 24.
Eric Volkman has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.